Progressive Supranuclear Palsy

Jenifer Pitman; Jana Ivanidze

doi:10.1007/978-3-030-82367-2_30

Progressive Supranuclear Palsy

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The use of imaging biomarkers in progressive supranuclear palsy, a 4R tauopathy, has been evolving, with classic diagnostic workup including MR for structural imaging and 123I-Iodoflupane SPECT for dopamine transporter-specific imaging. 18F-FDG PET has been applied in PSP in the research setting; however, it shows limited diagnostic accuracy. More recently, tau-specific PET tracers have been developed which hold promise in improving diagnostic accuracy, especially early in the disease course. Differentiating PSP from other atypical parkinsonian syndrome phenotypes as well as from other neurodegenerative etiologies is important for prognostic and therapeutic purposes. Tau-targeted PET imaging may aid in further elucidation of the pathophysiology of PSP and its variants with the hope of developing disease-modifying therapeutic agents.

Original language	English (US)
Title of host publication	Hybrid PET/MR Neuroimaging
Subtitle of host publication	A Comprehensive Approach
Publisher	Springer International Publishing
Pages	347-359
Number of pages	13
ISBN (Electronic)	9783030823672
ISBN (Print)	9783030823665
DOIs	https://doi.org/10.1007/978-3-030-82367-2_30
State	Published - Jan 1 2021
Externally published	Yes

Keywords

Atypical parkinsonian syndromes
PET/MRI
Progressive supranuclear palsy
Tauopathy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-82367-2_30

Cite this

@inbook{388e4bfb5f394172929b7f2db5372b6d,

title = "Progressive Supranuclear Palsy",

abstract = "The use of imaging biomarkers in progressive supranuclear palsy, a 4R tauopathy, has been evolving, with classic diagnostic workup including MR for structural imaging and 123I-Iodoflupane SPECT for dopamine transporter-specific imaging. 18F-FDG PET has been applied in PSP in the research setting; however, it shows limited diagnostic accuracy. More recently, tau-specific PET tracers have been developed which hold promise in improving diagnostic accuracy, especially early in the disease course. Differentiating PSP from other atypical parkinsonian syndrome phenotypes as well as from other neurodegenerative etiologies is important for prognostic and therapeutic purposes. Tau-targeted PET imaging may aid in further elucidation of the pathophysiology of PSP and its variants with the hope of developing disease-modifying therapeutic agents.",

keywords = "Atypical parkinsonian syndromes, PET/MRI, Progressive supranuclear palsy, Tauopathy",

author = "Jenifer Pitman and Jana Ivanidze",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2021",

month = jan,

day = "1",

doi = "10.1007/978-3-030-82367-2_30",

language = "English (US)",

isbn = "9783030823665",

pages = "347--359",

booktitle = "Hybrid PET/MR Neuroimaging",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Progressive Supranuclear Palsy

AU - Pitman, Jenifer

AU - Ivanidze, Jana

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - The use of imaging biomarkers in progressive supranuclear palsy, a 4R tauopathy, has been evolving, with classic diagnostic workup including MR for structural imaging and 123I-Iodoflupane SPECT for dopamine transporter-specific imaging. 18F-FDG PET has been applied in PSP in the research setting; however, it shows limited diagnostic accuracy. More recently, tau-specific PET tracers have been developed which hold promise in improving diagnostic accuracy, especially early in the disease course. Differentiating PSP from other atypical parkinsonian syndrome phenotypes as well as from other neurodegenerative etiologies is important for prognostic and therapeutic purposes. Tau-targeted PET imaging may aid in further elucidation of the pathophysiology of PSP and its variants with the hope of developing disease-modifying therapeutic agents.

AB - The use of imaging biomarkers in progressive supranuclear palsy, a 4R tauopathy, has been evolving, with classic diagnostic workup including MR for structural imaging and 123I-Iodoflupane SPECT for dopamine transporter-specific imaging. 18F-FDG PET has been applied in PSP in the research setting; however, it shows limited diagnostic accuracy. More recently, tau-specific PET tracers have been developed which hold promise in improving diagnostic accuracy, especially early in the disease course. Differentiating PSP from other atypical parkinsonian syndrome phenotypes as well as from other neurodegenerative etiologies is important for prognostic and therapeutic purposes. Tau-targeted PET imaging may aid in further elucidation of the pathophysiology of PSP and its variants with the hope of developing disease-modifying therapeutic agents.

KW - Atypical parkinsonian syndromes

KW - PET/MRI

KW - Progressive supranuclear palsy

KW - Tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85159467640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159467640&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-82367-2_30

DO - 10.1007/978-3-030-82367-2_30

M3 - Chapter

AN - SCOPUS:85159467640

SN - 9783030823665

SP - 347

EP - 359

BT - Hybrid PET/MR Neuroimaging

PB - Springer International Publishing

ER -

Progressive Supranuclear Palsy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this